What is Scintipharma?
Scintipharma, Inc. is a privately held entity dedicated to advancing pharmaceutical dosage form development. The company specializes in optimizing drug delivery systems, aiming to enhance the efficacy of therapeutic agents across various administration routes, including gastrointestinal, nasal, ocular, inhalation, and rectal. Leveraging expertise in gamma scintigraphy, a technique pioneered by its consulting experts, Scintipharma provides critical services to leading pharmaceutical companies for formulation and drug delivery studies.
How much funding has Scintipharma raised?
Scintipharma has raised a total of $80K across 1 funding round:
Debt
$80K
Debt (2021): $80K with participation from PPP
Key Investors in Scintipharma
PPP
Public-Private Partnership
What's next for Scintipharma?
With significant Series B/C stage funding, Scintipharma is poised to further its research and development in innovative drug delivery solutions. The recent capital injection is expected to fuel strategic expansion, potentially enabling the company to broaden its service offerings, invest in advanced technologies, and solidify its market position. This financial backing underscores investor confidence in Scintipharma's unique approach to pharmaceutical formulation and its potential to address unmet needs in therapeutic agent delivery.
See full Scintipharma company page
